Registry for patients with treatment-resistant depression and OCD receiving interventional therapies
Official title: University of Iowa Interventional Psychiatry Service Patient Registry
Run by University of Iowa · NCT04480918 · Data updated 2026-11-12
This study is testing different treatments like ECT, TMS, and ketamine to see how they help people with treatment-resistant depression and OCD feel better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University of Iowa Academic / other |
| Locations | 1 site (Iowa City, Iowa) |
| Status | Recruiting |
| Started | November 2, 2020 |
| Main results expected | August 2050 |
| Study ends | August 2050 |
| Registry record updated | March 3, 2026 |
| Trial ID | NCT04480918 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18-99 with a clinical diagnosis of major depressive disorder, bipolar disorder, or treatment-resistant OCD.
✕Probably not a fit
Patients with primary neuropsychiatric diagnoses other than major depressive disorder or bipolar disorder, or those with serious unstable medical conditions, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study examines the effects of various interventional therapies, such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine treatments, on patients with treatment-resistant depression (TRD) and obsessive-compulsive disorder (OCD). It aims to collect and analyze biomarkers, including neurobehavioral tests and neuroimaging, to better understand treatment responses. By identifying multimodal biomarkers, the study seeks to enhance personalized treatment approaches for individuals suffering from major depression and related disorders.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatment options for patients with treatment-resistant depression and OCD.
How similar studies have gone: Previous studies have shown promising early results in identifying biomarkers for treatment response in similar patient populations, but this approach aims to enhance predictive power through multimodal analysis.
Who can join: the full rules
Show full inclusion / exclusion criteria
INCLUSION CRITERIA: 1. 18-99 years of age 2. English-speaker with a level of understanding sufficient to agree to clinical treatment with a treatment modality offered by the Interventional Psychiatry Service, all required research procedures, and sign an informed consent document 3. Clinical diagnosis of a major depressive episode in the context of major depressive disorder or bipolar disorder or treatment-resistant OCD evaluated by a provider on the Interventional Psychiatry Service and felt to be an appropriate candidate for clinical treatment with a treatment modality offered by the Interventional Psychiatry Service. EXCLUSION CRITERIA: 1. Age less than 18 years 2. A primary neuropsychiatric diagnosis that is not either major depressive disorder or bipolar disorder 3. Serious, unstable medical conditions/problems including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease, e.g. uncontrolled asthma, uncontrolled hyper/hypothyroidism or active cancer. 4. Involuntary commitment to psychiatry inpatient units 5. If patients have one or more of the following MRI Exclusion criteria, they will not be able to participate in those aspects of this study: 1. The presence of an implanted device including pacemaker, coronary stent, defibrillator, or neurostimulation device that is not MRI-compatible 2. The presence of ferromagnetic objects in the body, i.e. bullets, shrapnel, and/or metal slivers 3. Clinically-significant claustrophobia 4. Clinically-significant hearing loss 5. Pregnant or nursing women or women of child bearing potential not using at least one medically accepted means of contraception (to include oral, injectable, or implant birth control, condom or diaphragm with spermicide, intrauterine devices (IUD), tubal ligation, abstinence, or partner with vasectomy) 6. The presence of any medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications
Where it's running
-
University of Iowa Health Care
Iowa City, Iowa, United States Recruiting
Study contacts
- Principal investigator: Mark J Niciu, M.D., Ph. D. — University of Iowa Hospitals & Clinics
- Study coordinator: Karin Nielsen, MS
- Email: karin-nielsen@uiowa.edu
- Phone: 319-384-6521
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
EEG-Guided TMS for Adults With Depression
This study tests whether delivering intermittent theta burst stimulation (iTBS) timed to brain waves using EEG can improve treatment for adults with major depressive disorder who have not responded to usual antidepressants.
-
EEG microstates and inflammatory markers in treatment-resistant depression patients undergoing ECT
This study tests how electroconvulsive therapy affects brain activity patterns seen in EEG and inflammatory biomarkers in adults with treatment-resistant major depression.
-
EEG microstates and inflammatory biomarkers in older adults with major depression receiving ECT
This study tests how ECT affects brain wave patterns and inflammatory markers in people 55 and older with major depression.
-
Sleep-to-Mood in Depression: Home-based tDCS
This study tests whether home-based tDCS for adults with moderate depression helps sleep improve and whether better sleep is linked to mood improvements.
-
Venous Tourniquet with Low-Dose Sugammadex vs Arterial Tourniquet for Seizure Monitoring During ECT
40 patients undergoing ECT will have a venous tourniquet on one arm and an arterial tourniquet on the other to see which method better reveals motor seizures.
-
Mindfulness‑augmented brain stimulation for treatment‑resistant depression
This trial will test whether combining fast brain stimulation (iTBS) with a digital mindfulness program helps people with treatment‑resistant depression reduce symptoms and improve thinking.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.